Results 121 to 130 of about 2,183 (157)

Raynaud's phenomenon on initiation of Lithium therapy: a case report. [PDF]

BMC Psychiatry
Boland C, Adams E, Wong MC, Denihan C.
europepmc   +1 more source

Lithium prescription patterns for bipolar disorder at a psychiatric hospital in KwaZulu-Natal. [PDF]

S Afr J Psychiatr
Motebele NN, Ntlantsana V, Mashaphu S, Saloojee S.   +3 more
europepmc   +1 more source

Chronic Treatment with Nigella sativa Oil Exerts Antimanic Properties and Reduces Brain Inflammation in Rats. [PDF]

Int J Mol Sci
Uzzan S, Rostevanov IS, Rubin E, Benguigui O, Marazka S, Kaplanski J, Agbaria R, Azab AN.   +7 more
europepmc   +1 more source

Safety Profile of Lithium: A Disproportionality Analysis Using the FDA Adverse Event Reporting System.

Neuropsychobiology
Zhu H, Guo J, Lui H, Ip P.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Depressive mania associated with nonresponse to antimanic agents

American Journal of Psychiatry, 1993
Of 39 patients consecutively admitted for the treatment of primary mania, 21 (53.8%) simultaneously met the Research Diagnostic Criteria for major depressive disorder ("mixed" or "depressive" mania). Only nine (42.9%) of the 21 patients with depressive mania responded to antimanic agents.
S C, Dilsaver, A C, Swann, A M, Shoaib, T C, Bowers, M T, Halle   +4 more
openaire   +3 more sources

The Ascendancy of Second-Generation Antipsychotics as Frontline Antimanic Agents

Journal of Clinical Psychopharmacology, 2015
Knowledge of the factors affecting the adoption of new medications can enhance mental health care and guide quality improvement and policy development. Food and Drug Administration indications for treating bipolar disorder with several second-generation antipsychotics (SGAs) in the 2000s represent an opportunity to identify factors that impact the ...
Christopher J, Miller, Mingfei, Li, Robert B, Penfold, Austin F, Lee, Eric G, Smith, Samuel S, Nordberg, David N, Osser, Laura, Bajor, Fang, Zhang, Mark S, Bauer   +9 more
openaire   +2 more sources

Antimanic and mood‐stabilizing effect of memantine as an augmenting agent in treatment‐resistant bipolar disorder

Bipolar Disorders, 2010
Memantine is a selective, uncompetitive N-methyl- D-aspartate (NMDA) receptor antagonist, currently used in the treatment of Alzheimers disease. Many clinical trials have demonstrated its tolerability and safety. We have suggested that antidepressants induce mania and rapid cycling by sensitizing dopamine D2 receptors and demonstrated that the ...
Athanasios Koukopoulos, Daniela Reginaldi, SERRA, GIULIA, KOUKOPOULOS, ALEXIA, SANI, Gabriele, Gino Serra   +5 more
openaire   +3 more sources

Structurally Dissimilar Antimanic Agents Modulate Synaptic Plasticity by Regulating AMPA Glutamate Receptor Subunit GluR1 Synaptic Expression

Annals of the New York Academy of Sciences, 2003
Abstract: A growing body of data from clinical and preclinical studies suggests that the glutamatergic system may represent a novel therapeutic target for severe recurrent mood disorders. Since synapse‐specific glutamate receptor expression/localization is known to play critical roles in synaptic plasticity, we investigated the effects of mood ...
Jing, Du, Neil A, Gray, Cynthia, Falke, Peixiong, Yuan, Steven, Szabo, Husseini K, Manji   +5 more
openaire   +2 more sources